Sign up to save your podcasts
Or
Share Jesus G. Berdeja, MD - Optimizing Outcomes in Relapsed/Refractory Multiple Myeloma With Bispecific Antibodies: A Community Clinician's Roadmap
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Jesus G. Berdeja, MD - Optimizing Outcomes in Relapsed/Refractory Multiple Myeloma With Bispecific Antibodies: A Community Clinician's Roadmap
Please visit answersincme.com/RJB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in multiple myeloma discuss strategies for incorporating bispecific antibodies into the treatment of heavily pretreated relapsed/refractory multiple myeloma RRMM in the community setting. Upon completion of this activity, participants should be better able to: Review the role of bispecific antibodies in the current treatment landscape of RRMM; Discuss the clinical profiles of approved and late-stage emerging bispecific antibodies in heavily pretreated RRMM; Describe strategies to optimize outcomes with bispecific antibodies for the treatment of RRMM; and Outline practical considerations for incorporating bispecific antibodies into the treatment of heavily pretreated RRMM in the community setting. This activity is intended for US healthcare professionals only.
View all episodes
By Answers in CME
5
55 ratings
Please visit answersincme.com/RJB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in multiple myeloma discuss strategies for incorporating bispecific antibodies into the treatment of heavily pretreated relapsed/refractory multiple myeloma RRMM in the community setting. Upon completion of this activity, participants should be better able to: Review the role of bispecific antibodies in the current treatment landscape of RRMM; Discuss the clinical profiles of approved and late-stage emerging bispecific antibodies in heavily pretreated RRMM; Describe strategies to optimize outcomes with bispecific antibodies for the treatment of RRMM; and Outline practical considerations for incorporating bispecific antibodies into the treatment of heavily pretreated RRMM in the community setting. This activity is intended for US healthcare professionals only.
More shows like CME in Minutes: Education in Oncology & Hematology
View all
JAMA Editors' Summary
129 Listeners
NEJM This Week
317 Listeners
Journal of Clinical Oncology (JCO) Podcast
42 Listeners
This Week in Cardiology
851 Listeners
JAMA Clinical Reviews
480 Listeners
The Curbsiders Internal Medicine Podcast
3,335 Listeners
JAMA Medical News
88 Listeners
CME in Minutes: Education in Cardiology & Pulmonology
3 Listeners
CME in Minutes: Education in Dermatology
3 Listeners
CME in Minutes: Education in Primary Care
5 Listeners
CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases
4 Listeners
CME in Minutes: Education in Ophthalmology
0 Listeners